Member Info for TrekMadone

Reading bbc news a vaccine could be out in September. We got to get that test out quick. I believe you still need the test even if there is a vaccine but it’s what the market thinks.

I’m just hoping it’s ready and they are doing field trials before submission to tune it so it goes in as a whole project. Could do with some news soon.

Trek

Yes thanks seeker but I can’t fathom why we are not up today. As I say market concerns around what ‘a nominal fund’ is. OO have also been investing in new machinery, not rnsd as not material, they obviously have a home for cash with all that’s going on,

Would have been better if rns said out of existing cash, rather than leaving it with 3 months etc. I get they don’t want to disclose amount but it may be that’s what the concern is here. Obviously it’s just a guess.

Trek

I can only think the market is concerned about a placing to finance. Everything else seems positive. ‘A nominal fund’, is vague but if there is a raise of sorts and it’s accretive and drives the bottom line it doesn’t matter.

Companies list here to grow, if it’s equity it’s not necessarily dilutive as we add capex. If it’s a loan it’ll be repaid from extra revenue. The market will get it soon. All imo.

Trek

Once North finish I’m not sure where the sells in any volume will come from. I’m not selling any and I doubt many PI’s will. There’s always a few traders but I just don’t see the buy side being supported any time soon. I think we could be due a pop. 5-7p in one hit possibly followed by another if that doesn’t flush some shares out.

Trek

Totally agree. Smart move drive synergy, cut costs, up capacity becomes more efficient. We defo need capacity!

And the sp falls. Give up!

Trek

Just had similar RNS re Numis from GGP their headline was...

“Joint broker update”

as opposed to

“resignation of joint broker”

The former is more conducive to a steady hand when putting!

Trek

Hi kwaboy,

This is where imo some ceo’s need to be a bit more streetwise in this jungle. RM doesn’t have to do much just bark at the broker about looking after the company interest as they are paid to do. If it was oversubscribed put two heads together, place shares and move on.

What if we get a takeover approach or need another raise with Acacia selling does RM just say let’s take what’s there? You get the gist.

I don’t expect RM to waste time on it but I do expect VFM from the broker.

Trek

Hi Jody,

I am an investor in Synairgen and am concerned at the apparent stock overhang from Acacia. If it is there intention to sell their remaining holding can the shares be placed.

I draw a comparison with 4D Pharma that were in a similar situation and their broker managed to place all of Acacia’s 8.99% holding with institutions. This was because like Synairgen they had recently completed an oversubscribed fundraise and there was an appetite for the stock.

Would you be able to pass this communication to the right decision maker as it may be that finnCap could help with this process.

As an investor my concern is that the impending results, good or bad, could be sold into by Acacia having a severely disproportionate affect on the share price.

Kindest Regards,

Trek,

Ah, RTN,

Just saw your post after I sent the email. Still SNG should have an investor relations email address on their website. Hopefully it want be too onerous for Jody to bump on.

Trek

Has anyone got an email address from the company. Been looking around website and can only find phone numbers and addresses. Thanks

Trek

Is it just me or does AK take some perverse pleasure in scaring the sht out of us with some of his RNS headlines!

Trek

Just looking back through the RNS’s

Placing for £30m 8th Dec at £7.90 no placings before that are listed here but obviously there would have been or an IPO since founding in 2014. 4D took over some other companies in the early years so would need cash.

Since then they listed 82349 shares as part of Biomar acquisition 8th April 2016

Then from the 8th Oct 2019 RNS, worth reading again. How close are we to....

“Under the terms of the agreement 4D's proprietary MicroRx® platform will be paired with MSD's expertise in the development and commercialisation of novel vaccines, to discover and develop LBPs as vaccines in up to three undisclosed indications. 4D has the right, subject to certain conditions, to cause MSD to purchase $5 million in ordinary shares in 4D during the first 12 months of the collaboration. In addition to an upfront cash payment, for each indication, 4D will be eligible to receive up to $347.5 million in option exercise and development and regulatory milestone payments, plus tiered royalties on annual net sales of any licensed products derived from the collaboration. MSD will be responsible for development, manufacturing and commercialisation following the exercise of any of its exclusive options.”

Then 18th Feb 2020 placing 4D met conditions to cause MSD to contribute $5m, a total of £22m raised.

Then £7.7m raised on 13th July 2020.

Hardly a habitual diluter on investors. But that said the mcap now is £40m. When you look at what has been raised and what has been achieved and yet aim has attributed hardly any value. Even if you look at the directors buys, significant sums around 90p!

This surely has to be bargain basement territory. It just seems that AIM lets a share price rise, pump and then it just pulls the rug from under it. Catching investors out, taking more money with false dawns as they average down. It’s a cruel market as the SP is not a reflection of our research or our view of value and that’s how us PI’s get done over.

The thing is though it does reach a bottom at some point and then if a couple of price inflections kick in, boom! You then can’t get back on the ladder or you sit an watch and think it will pull back, it doesn’t and then you can run the risk of being spiked.

I do think though stripping it back. If 4D does hit those triggers you can’t hide $347.5m. And there’s more than that. That is when true value will out.

Question is do you buy now or wait for 23p or 5p. Who knows. It could be that 35p is the last of it and it takes off from here. All I will say is we are close now and the directors who are underwater also put more in.

Even though I didn’t buy until after the Feb placing so am now underwater I’m pretty confident to hold here and trust this BoD to do their work. They’ve done pretty well so far but of course we are not at the end yet so jury is still out.

Trek

‘‘Tis for Merck, IF we get close to those triggers they have to pay 350 odd million to 4D as first payment. Why do that when you can buy the company. Hence no brainer but granted it’s a big if.

Trek

Proactive from yesterday

“Directa Plus PLC (LON:DCTA) has revealed that its Setcar has bagged its third major contract win since the AIM-listed company bought a controlling stake in November 2019.

Setcar has signed a contract to supply total waste management services to Cummins Generator Technologies Romania, a part of the Fortune 500 company, Cummins.

The contract is valued at around US$3mln over three years from October 1, 2020.

Directa Plus's Grafysorber technology will be used in the services provided by Setcar.

"This third major contract win since acquiring Setcar as a subsidiary illustrates the potential for growth in our key environmental vertical. We hope to demonstrate further market penetration in industrial and oil and gas markets as we continue to roll out Setcar's services during the remainder of 2020," Giulio Cesareo, the founder and chief executive officer of Directa Plus said in a statement.”

https://www.proactiveinvestors.co.uk/companies/news/923973/directa-plus-says-setcar-subsidiary-bags-us3mln-contract-923973.html

Trek

Jimmy,

Look at my earlier post. Assume Mrx0518 works with Keytruda. Will Merck pay over 1bn in 3 payments to a 40m mcap Co? Keytruda’s revenue is +7bn a year and growing. If mrx enhances the performance 4D get also get tiered royalties. These are massive sums!

We don’t have all the detail, so the triggers are not known but if they get close to achieving the milestones it’s a virtual no brainer that MSD will bid to save paying out 1bn +. Even 500m would be a bargain.

So yes I think we will be taken out but no idea for how much.

Trek

Outlook is neutral. Trading range is 1.65-2.25. 20dma is coming back up through the 100 and 50 which means we should just stay north of 2p for a while.

The exciting thing here is the news spike. Next news could take us through 4.35 and establish a higher channel at 4p.

https://www.marketscreener.com/KATORO-GOLD-PLC-22033612/charts/

Trek

Well done and dusted. Plenty of appetite for them shares. Hopefully we see some buying on the open market.

Half a million quid from the directors on top of the 50p is some backing!

On the basis of the average of the two placings we may get back to the 40’s again pretty quickly. I’m still convinced we will have a 10-20% rise day soon. 131m shares is not a lot. Seen billions for Oiler’s with similar mcap.

Been thinking though that 7.7m is an odd number and February seemed a little specific. I have no doubt they could have raised 20m if needed. Just wondering if the directors are really confident that the next raise, if there is one, will be much higher or even we’d be sold. The ops update was very good so let’s hope we start to see those £millions of R&D reflected in the sp!

Trek

This momentum should carry on for a while. It’s clearly a long anticipated breakout, just what some folk may have been waiting for. Unfortunately I’m fully invested else i’d add more.

Trek

Was the RNS really that bad. This is pioneering technology there are always snags. The cash is good and the DoD contract is looking good. The rest is on track technically albeit slower than we’d hope.

Much of the fall has been exacerbated by the illiquidity with there being so few shares for a small mcap. Ironically one of the attractions for investing here, hence it goes down ‘disproportionately’ but it should also rise ‘disproportionately’.

Many folk here will need a 100% rise to get back to evens. That’s only £38m which with the right news is achievable.

The problem that we will have from here is traders buying now and selling into news. It’s all part and parcel but they should be out fairly quickly.

The poc rapid test due end of year will imo change everything. That’s primarily why I invested. I truly believe that that will be massively transformational. It will be a superior bit of kit that many establishments will want on hand.

Trek

Flipping heck pop out for ten minutes and we get an RNS....

I am surprised that they raised so early, I thought there was enough cash until Christmas. I don’t know if the covid trial has accelerated the cash burn. Having judged the timing wrong I am now obviously concerned that the next rise comes earlier. Remember they promised 2 clinical readouts from the Feb money, so as a plus we now get an extra two readouts for 7.7m

16.7% dilution is not a lot but it’s the cumulative effect. Operationally the RNS was an amazing read! These guys have really been on their game and moving at pace and the results look extremely encouraging and it’s well written.

Sure the bookbuild is done already we’ll get the RNS probably in an hour or so and the directors have put in even more money. Unfortunately though my resources don’t extend to buying anymore so now I, like many, am pretty stuck until the first penalty kick. It better be an open goal and they better not miss!

This was the other ray of hope to truly transform the SP in the short term... I’ll be happier if we see that first payment soon!

“The Directors believe that the Company's recent vaccines research collaboration and option to license agreement with MSD (the tradename of Merck & Co., Inc, Kenilworth, NJ USA) which, in addition to the $5 million invested in the Company by MSD (the tradename of Merck & Co., Inc, Kenilworth, NJ USA) as part of the February Fundraise, includes an upfront cash payment and, if exercised, the possibility of up to $347.5 million in option exercise and development and regulatory milestone payments for each of up to three indications (potentially totaling over $1.04 billion), and tiered royalties on annual net sales of any licensed products derived from the collaboration, is a validation of the strength of the Company's research and development capabilities.”

Trek

I hold quite a few ‘covid plays’. I have just reread the trading update RNS and looked around the web page. I must say i’m pretty envious of those buying now. For me to average down here i’d have to sell elsewhere or sell here hoping to buy back lower. Neither of which I am prepared to do.

Imo the approvals will come and it will lift. The rapid test poc is the buggy, end of year.

Trek